论文部分内容阅读
用杂交瘤技术制备了抗呼吸道合胞病毒 (RSV Long株 )的单克隆抗体F3细胞株。经IFA及ELISA证明 ,F3株McAb对RSV抗原特异 ,具中和活性及融合抑制活性 ,其腹水中和效价和融合抑制效价分别为 1∶12 8和 1∶6 4。将F3株McAb与商售混合单抗试剂盒进行临床诊断比较 ,二者阳性符合率 96 .9% ,阴性符合率 10 0 %。
The monoclonal antibody F3 cell line against respiratory syncytial virus (RSV Long strain) was prepared by hybridoma technique. The results of IFA and ELISA showed that McAb F3 was specific for RSV antigen and had neutralizing activity and fusion inhibition activity. The ascites neutralization potency and fusion inhibition potency were 1:12 8 and 1:6 4, respectively. The clinical isolates of McAb F3 and commercial mixed monoclonal antibody were compared, the positive coincidence rate was 96.9% and the negative coincidence rate was 100%.